JoVE Search Results: Cytogenetic Abnormalities

Impact
Papers
Jobs
Conferences

Name	Impact ?	Papers	Institution	Country	Funding
Levine, Ross L	585	20	Memorial Sloan-Kettering Cancer Center	USA	$5,481,400.00
Bloomfield, Clara D	575.1	19	The Ohio State University Comprehensive Cancer Center	USA	$5,706,939.00
Haferlach, Torsten	449.2	36	MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich	Germany	-
Tefferi, Ayalew	366.1	28	Mayo Clinic	USA	-
Tien, H-F	364	19	National Taiwan University Hospital	Taiwan	-
Döhner, Konstanze	343.4	13	University Hospital of Ulm	Germany	-
Maciejewski, Jaroslaw P	338	21	Cleveland Clinic	USA	$9,230,615.00
Wilson, Richard K	257.1	2	Washington University	USA	$216,151,607.00
Mullighan, Charles G	247.1	13	University of California	USA	$4,986,633.00
van den Heuvel-Eibrink, M M	245.2	17	Erasmus MC-Sophia Children's Hospital	Netherlands	-
Ebert, Benjamin L	244.6	10	Harvard Medical School	USA	-
Graubert, Timothy A	229.5	5	Washington University School of Medicine	USA	$7,041,673.00
Tallman, Martin S	222.1	14	Roosevelt Hospital Center	USA	-
Bhatia, Ravi	220.5	6	Division of Hematopoietic Stem Cell and Leukemia Research and.	N/A	$4,251,368.00
Garcia-Manero, Guillermo	213.6	22	The University of Texas MD Anderson Cancer Center	USA	$292,600.00
Kantarjian, Hagop	212	19	The University of Texas M. D. Anderson Cancer Center	USA	$12,195,814.00
Meshinchi, Soheil	209.5	10	Clinical Research Division	USA	$1,905,477.00
Cortes, Jorge	208.9	27	The University of Texas MD Anderson Cancer Center	USA	$8,473,811.00
Weissman, Irving L	202.3	5	Stanford University	USA	$18,173,133.00
Ley, Timothy J	202.3	8	Washington University School of Medicine	USA	$28,223,390.00
Chen, Sai-Juan	198.2	8	Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine	China	-
Ravandi, F	193.4	17	The University of Texas MD Anderson Cancer Center	USA	-
Döhner, Hartmut	192.3	6	Comprehensive Cancer Center	USA	-
Dombret, Hervé	190.1	11	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	France	-
Estey, Elihu H	178.2	11	Stanford University School of Medicine	USA	-
Scott, Hamish S	177.6	2	Department of Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, South Australia	Australia	-
Falini, Brunangelo	177	8	Munich Leukemia Laboratory GmbH, Munich	Germany	-
Andreeff, M	170.2	12	University of Texas M. D. Anderson Cancer Center	USA	-
Kantarjian, Hagop M	165.3	12	MD Anderson Cancer Center	USA	-
Carroll, M	164	8	University of Pennsylvania	USA	-
Pabst, Thomas	161.4	7	University Hospital and University of Berne	Switzerland	-
Appelbaum, Frederick R	160.6	12	Stanford Cancer Center	USA	-
Campana, Dario	160.2	9	St Jude Children's Research Hospital	USA	$1,647,044.00
Hsu, Katharine C	159.9	1	Memorial Sloan-Kettering Cancer Center	USA	$3,245,354.00
Marcucci, Guido	156.6	9	The Ohio State University	USA	$7,902,249.00
Relling, Mary V	149.7	7	St Jude Children's Research Hospital	USA	$11,471,423.00
Armstrong, Scott A	148.4	7	Harvard Medical School	USA	$9,205,355.00
Stegmaier, Kimberly	147.9	4	Harvard Medical School	USA	$1,841,773.00
DiPersio, John F	147.5	3	Washington University School of Medicine	USA	$6,990,653.00
Scadden, David T	142.1	2	Massachusetts General Hospital	USA	$23,872,119.00
Weisdorf, Daniel J	140.3	13	Mayo Clinic Rochester	USA	$3,677,713.00
Sung, L	138	18	Children's Hospital of Eastern Ontario	Canada	-
Jansen, Joop H	136.3	3	Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences	Netherlands	-
Melnick, Ari	135.9	3	Weill Cornell Medical College	USA	$6,068,155.00
Löwenberg, Bob	133.8	5	University Hospital La Fe	Spain	-
Heuser, Michael	132.6	10	Hannover Medical School	Germany	-
Björkholm, Magnus	130	3	Genetic Epidemiology Branch, DCEG, NCI, 6120 Executive Blvd, Room 7124, MSC 7236, Bethesda, MD 20892-7236	USA	-
Pui, Ching-Hon	127.8	11	St Jude Children's Research Hospital	USA	-
Ganser, Arnold	125.9	7	Hannover Medical School	Germany	-
Delwel, Ruud	124.4	7	Erasmus University Medical Center	Netherlands	-

Name	Institution	Date	Impact	Publication
Tefferi, Ayalew	Mayo Clinic	04/15/2009	101.70	CA: a cancer journal for clinicians Advances in understanding and management of myeloproliferative neoplasms. Abstract
Hsu, Katharine C	Memorial Sloan-Kettering Cancer Center	08/30/2012	53.29	The New England journal of medicine HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. Abstract
Graubert, Timothy A	Washington University School of Medicine	03/14/2012	53.29	The New England journal of medicine Clonal architecture of secondary acute myeloid leukemia. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	03/14/2012	53.29	The New England journal of medicine Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Abstract
Ebert, Benjamin L	Harvard Medical School	06/30/2011	53.29	The New England journal of medicine Clinical effect of point mutations in myelodysplastic syndromes. Abstract
Falini, Brunangelo	University of Perugia	06/11/2011	53.29	The New England journal of medicine BRAF mutations in hairy-cell leukemia. Abstract
Pabst, Thomas	UniversitÃ¤tsspital Basel , Basel	03/17/2011	53.29	The New England journal of medicine Cytarabine dose for acute myeloid leukemia. Abstract
Wilson, Richard K	Washington University	11/10/2010	53.29	The New England journal of medicine DNMT3A mutations in acute myeloid leukemia. Abstract
Tallman, Martin S	Israel Institute of Technology	09/24/2009	53.29	The New England journal of medicine Anthracycline dose intensification in acute myeloid leukemia. Abstract
Ley, Timothy J	Washington University Medical School	08/05/2009	53.29	The New England journal of medicine Recurring mutations found by sequencing an acute myeloid leukemia genome. Abstract
Relling, Mary V	St Jude Children's Research Hospital	06/25/2009	53.29	The New England journal of medicine Treating childhood acute lymphoblastic leukemia without cranial irradiation. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	03/22/2013	38.27	Lancet Acute lymphoblastic leukaemia. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	08/17/2012	37.54	Nature reviews. Cancer The role of mutations in epigenetic regulators in myeloid malignancies. Abstract
DiPersio, John F	Washington University School of Medicine	01/11/2012	36.28	Nature Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	01/11/2012	36.28	Nature The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	07/07/2013	35.53	Nature genetics Somatic SETBP1 mutations in myeloid malignancies. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	09/23/2012	35.53	Nature genetics Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Abstract
Scott, Hamish S	Department of Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, South Australia	12/27/2011	35.53	Nature genetics Spliceosome mutations in hematopoietic malignancies. Abstract
Scott, Hamish S	Department of Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, South Australia	09/04/2011	35.53	Nature genetics Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Abstract
Chen, Sai-Juan	Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine	03/13/2011	35.53	Nature genetics Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Abstract
Jansen, Joop H	Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences	07/04/2010	35.53	Nature genetics Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	08/27/2009	35.53	Nature genetics Inherited susceptibility to pediatric acute lymphoblastic leukemia. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	06/26/2009	35.53	Nature genetics TET2 mutations in myelodysplasia and myeloid malignancies. Abstract
Jansen, Joop H	Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences	05/31/2009	35.53	Nature genetics Acquired mutations in TET2 are common in myelodysplastic syndromes. Abstract
Wilson, Richard K	Washington University	07/23/2012	32.40	Cell The origin and evolution of mutations in acute myeloid leukemia. Abstract
Scadden, David T	Massachusetts General Hospital	09/02/2011	32.40	Cell AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Abstract
Weissman, Irving L	Stanford University	07/27/2009	32.40	Cell CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Abstract
Weissman, Irving L	Stanford University School of Medicine	07/27/2009	32.40	Cell CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Abstract
Armstrong, Scott A	Harvard Medical School	03/26/2010	31.20	Science (New York, N.Y.) The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Abstract
Relling, Mary V	St Jude Children's Research Hospital	01/29/2009	30.02	JAMA Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. Abstract
Ebert, Benjamin L	Harvard Medical School	06/13/2013	26.56	Cancer cell In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	08/17/2012	26.56	Cancer cell Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	08/17/2012	26.56	Cancer cell ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Abstract
Bhatia, Ravi	Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, CA 91010	04/20/2012	26.56	Cancer cell Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Abstract
Bhatia, Ravi	Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, CA 91010	02/20/2012	26.56	Cancer cell Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Abstract
Bhatia, Ravi	Division of Hematopoietic Stem Cell and Leukemia Research and.	11/18/2011	26.56	Cancer cell Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Abstract
Ebert, Benjamin L	Harvard Medical School	11/18/2011	26.56	Cancer cell Power cut: inhibiting mitochondrial translation to target leukemia. Abstract
Carroll, Martin	University of Pennsylvania	09/12/2011	26.56	Cancer cell Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	07/11/2011	26.56	Cancer cell The role of TET2 in hematologic neoplasms. Abstract
Armstrong, Scott A	Harvard Medical School	07/11/2011	26.56	Cancer cell MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	06/30/2011	26.56	Cancer cell Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Abstract
Weissman, Irving L	Stanford University School of Medicine	01/21/2011	26.56	Cancer cell Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye. Abstract
Melnick, Ari	Weill Cornell Medical College	12/09/2010	26.56	Cancer cell Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	10/18/2010	26.56	Cancer cell T-lineage lymphoblastic lymphoma and leukemia-a MASSive problem. Abstract
Marcucci, Guido	The Ohio State University	04/13/2010	26.56	Cancer cell Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Abstract
Armstrong, Scott A	Harvard Medical School	02/04/2010	26.56	Cancer cell HELP for AML: methylation profiling opens new avenues. Abstract
Melnick, Ari	Weill Cornell Medical College	01/07/2010	26.56	Cancer cell DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Abstract
Stegmaier, Kimberly	Harvard Medical School	10/05/2009	26.56	Cancer cell Proteomic and genetic approaches identify Syk as an AML target. Abstract
Pui, Ching-Hon	St Jude Children's Research Hospital	02/02/2009	26.56	Cancer cell T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	04/09/2012	25.42	Cell stem cell Targeting β-catenin in CML: leukemia stem cells beware! Abstract
Campana, Dario	National University of Singapore	05/05/2010	22.58	The Lancet. Oncology Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Abstract
Campana, Dario	National University of Singapore	01/13/2009	22.58	The Lancet. Oncology Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Abstract
Scadden, David T	Massachusetts General Hospital	10/27/2013	22.46	Nature medicine Differential regulation of myeloid leukemias by the bone marrow microenvironment. Abstract
Ebert, Benjamin L	Harvard Medical School	08/28/2012	20.00	Annual review of pathology Molecular pathophysiology of myelodysplastic syndromes. Abstract
Bloomfield, Clara D	The Ohio State University Comprehensive Cancer Center	12/30/2013	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. Abstract
Bloomfield, Clara D	The Ohio State University	05/06/2013	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. Abstract
Pui, Ching-Hon	St Jude Children's Research Hospital	05/06/2013	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. Abstract
Dombret, Hervé	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	12/17/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	11/19/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. Abstract
Delwel, Ruud	Erasmus University Medical Center	09/24/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Abstract
Bloomfield, Clara D	The Ohio State University	09/17/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. Abstract
Campana, Dario	National University of Singapore	09/10/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. Abstract
Ebert, Benjamin L	Harvard Medical School	08/06/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Abstract
Bloomfield, Clara D	The Ohio State University Comprehensive Cancer Center	07/02/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Abstract
Kantarjian, Hagop M	MD Anderson Cancer Center	05/14/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Abstract
Kantarjian, Hagop M	The University of Texas MD Anderson Cancer Center	05/14/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. Abstract
Löwenberg, Bob	University Hospital La Fe	05/07/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. Abstract
Döhner, Konstanze	University Hospital of Ulm	03/19/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	02/27/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. Abstract
Bloomfield, Clara D	The Ohio State University	01/30/2012	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Abstract
Björkholm, Magnus	Genetic Epidemiology Branch, DCEG, NCI, 6120 Executive Blvd, Room 7124, MSC 7236, Bethesda, MD 20892-7236	12/12/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes. Abstract
Estey, Elihu H	Stanford University School of Medicine	10/03/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	09/26/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	07/11/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Abstract
Heuser, Michael	Hannover Medical School	06/13/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Abstract
Ganser, Arnold	Hannover Medical School	05/16/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. Abstract
Ravandi, Farhad	M.D. Anderson Cancer Center	05/09/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. Abstract
Döhner, Konstanze	University Hospital of Ulm	05/09/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Abstract
Bloomfield, Clara D	The Ohio State University Comprehensive Cancer Center	02/22/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract
Döhner, Konstanze	University Hospital of Ulm	02/22/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. Abstract
Ebert, Benjamin L	Harvard Medical School	01/10/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Unraveling the molecular pathophysiology of myelodysplastic syndromes. Abstract
Döhner, Hartmut	Comprehensive Cancer Center	01/10/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. Abstract
Heuser, Michael	Hannover Medical School	01/04/2011	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. Abstract
Meshinchi, Soheil	Clinical Research Division	12/28/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. Abstract
Relling, Mary V	St Jude Children's Research Hospital	12/20/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Improved prognosis for older adolescents with acute lymphoblastic leukemia. Abstract
Bloomfield, Clara D	The Ohio State University	11/15/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract
Döhner, Hartmut	UniversitÃ¤tsklinikum Ulm, Ulm	08/30/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. Abstract
Döhner, Hartmut	Comprehensive Cancer Center	07/26/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. Abstract
Kantarjian, Hagop M	The University of Texas M. D. Anderson Cancer Center	07/26/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	07/19/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Abstract
Döhner, Konstanze	University Hospital of Ulm	07/12/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. Abstract
Döhner, Konstanze	University Hospital of Ulm	06/21/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Abstract
Meshinchi, Soheil	Clinical Research Division	04/26/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. Abstract
Bloomfield, Clara D	The Ohio State University	04/05/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract
Delwel, Ruud	Erasmus University Medical Center	03/22/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. Abstract
Estey, Elihu H	Clinical Research Division and Southwest Oncology Group Statistical Center	02/16/2010	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. Abstract
DiPersio, John F	Washington University School of Medicine	12/21/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. Abstract
Bloomfield, Clara D	The Ohio State University	12/21/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	12/14/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	12/14/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	11/09/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Abstract
Relling, Mary V	St Jude Children's Research Hospital	11/09/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	11/02/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Abstract
Löwenberg, Bob	University Hospital La Fe	10/26/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	09/21/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. Abstract
Kantarjian, Hagop M	The University of Texas M. D. Anderson Cancer Center	08/31/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. Abstract
Andreeff, Michael	The University of Texas MD Anderson Cancer Center	08/03/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Abstract
Weisdorf, Daniel J	University of Minnesota	07/06/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. Abstract
Ganser, Arnold	Hannover Medical School	04/20/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Abstract
Björkholm, Magnus	Genetic Epidemiology Branch, DCEG, NCI, 6120 Executive Blvd, Room 7124, MSC 7236, Bethesda, MD 20892-7236	03/16/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden. Abstract
Bhatia, Ravi	Division of Hematopoietic Stem Cell and Leukemia Research and.	01/05/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. Abstract
Dombret, Hervé	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	01/05/2009	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	12/15/2008	18.37	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	11/11/2013	13.85	The Journal of experimental medicine Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	04/05/2010	13.85	The Journal of experimental medicine Metabolism and the leukemic stem cell. Abstract
Pui, C H	St Jude Children's Research Hospital	08/27/2012	13.75	Journal of the National Cancer Institute Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	09/03/2013	13.06	The Journal of clinical investigation Isocitrate dehydrogenase mutations in leukemia. Abstract
Andreeff, Michael	The University of Texas MD Anderson Cancer Center	05/08/2013	13.06	The Journal of clinical investigation CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	10/01/2012	13.06	The Journal of clinical investigation Molecular genetics of B-precursor acute lymphoblastic leukemia. Abstract
Stegmaier, Kimberly	Harvard Medical School	02/13/2012	13.06	The Journal of clinical investigation The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. Abstract
Ley, Timothy J	Siteman Cancer Center	05/31/2011	13.06	The Journal of clinical investigation PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	03/23/2011	13.06	The Journal of clinical investigation Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models. Abstract
Ley, Timothy J	Siteman Cancer Center	03/23/2011	13.06	The Journal of clinical investigation Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. Abstract
Carroll, Martin	University of Pennsylvania	12/13/2010	13.06	The Journal of clinical investigation BCR-ABL kinase is dead; long live the CML stem cell. Abstract
Carroll, Martin	University of Pennsylvania	12/13/2010	13.06	The Journal of clinical investigation Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. Abstract
Andreeff, Michael	University of Texas MD Anderson Cancer Center	12/21/2009	13.06	The Journal of clinical investigation Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. Abstract
Ley, Timothy J	Washington University Medical School	05/18/2009	13.06	The Journal of clinical investigation High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. Abstract
Heuser, Michael	Hannover Medical School	12/13/2013	9.90	Blood Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	10/22/2013	9.90	Blood Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Abstract
Appelbaum, Frederick R	and University of Washington School of Medicine	10/03/2013	9.90	Blood A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Abstract
Marcucci, Guido	The Ohio State University	10/01/2013	9.90	Blood Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	08/23/2013	9.90	Blood Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Abstract
Heuser, Michael	Hannover Medical School	08/16/2013	9.90	Blood Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Abstract
Bhatia, Ravi	Division of Hematopoietic Stem Cell and Leukemia Research and.	07/29/2013	9.90	Blood The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	07/29/2013	9.90	Blood Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Abstract
Appelbaum, Frederick R	Clinical Research Division	07/11/2013	9.90	Blood Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Abstract
Andreeff, Michael	University of Texas MD Anderson Cancer Center	06/05/2013	9.90	Blood Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Abstract
Döhner, Konstanze	University Hospital of Ulm	05/23/2013	9.90	Blood Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	05/03/2013	9.90	Blood Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Abstract
Döhner, Konstanze	University Hospital of Ulm	04/30/2013	9.90	Blood Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Abstract
Andreeff, Michael	The University of Texas MD Anderson Cancer Center	04/05/2013	9.90	Blood Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	02/28/2013	9.90	Blood Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Abstract
Löwenberg, Bob	University Hospital La Fe	01/04/2013	9.90	Blood Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Abstract
Döhner, Konstanze	University Hospital of Ulm	10/31/2012	9.90	Blood Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Abstract
Marcucci, Guido	The Ohio State University	10/25/2012	9.90	Blood Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	10/15/2012	9.90	Blood Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Abstract
Löwenberg, Bob	University Hospital La Fe	10/09/2012	9.90	Blood Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Abstract
Tefferi, Ayalew	Mayo Clinic	09/11/2012	9.90	Blood SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	08/29/2012	9.90	Blood The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Abstract
Pabst, Thomas	UniversitÃ¤tsspital Basel , Basel	08/22/2012	9.90	Blood The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	08/09/2012	9.90	Blood Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Abstract
Jansen, Joop H	Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences	07/11/2012	9.90	Blood High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. Abstract
Relling, Mary V	St Jude Children's Research Hospital	06/22/2012	9.90	Blood Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Abstract
Meshinchi, Soheil	Clinical Research Division	05/30/2012	9.90	Blood Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	05/02/2012	9.90	Blood Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Abstract
Campana, Dario	St Jude Children's Research Hospital	04/19/2012	9.90	Blood Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Abstract
Delwel, Ruud	Erasmus University Medical Center	04/05/2012	9.90	Blood Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	03/22/2012	9.90	Blood Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	03/19/2012	9.90	Blood EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Abstract
Heuser, Michael	Hannover Medical School	03/02/2012	9.90	Blood Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Abstract
Meshinchi, Soheil	Clinical Research Division	02/29/2012	9.90	Blood Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	02/09/2012	9.90	Blood Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Abstract
Chen, Sai-Juan	Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine	02/07/2012	9.90	Blood Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Abstract
DiPersio, John F	Washington University School of Medicine	02/02/2012	9.90	Blood A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	01/06/2012	9.90	Blood Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich	12/29/2011	9.90	Blood Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Abstract
Döhner, Hartmut	UniversitÃ¤tsklinikum Ulm, Ulm	12/20/2011	9.90	Blood TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Abstract
Tallman, Martin S	From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt…	12/16/2011	9.90	Blood "Boldness be my friend" (Shakespeare; Cymbeline). Abstract
Relling, Mary V	St Jude Children's Research Hospital	11/23/2011	9.90	Blood Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Abstract
Dombret, Hervé	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	11/18/2011	9.90	Blood Gene mutation and AML pathogenesis. Abstract
Tefferi, Ayalew	Mayo Clinic	11/17/2011	9.90	Blood SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	11/10/2011	9.90	Blood DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Abstract
Bloomfield, Clara D	The Ohio State University Comprehensive Cancer Center	10/26/2011	9.90	Blood ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Abstract
Falini, Brunangelo	Munich Leukemia Laboratory GmbH, Munich	10/19/2011	9.90	Blood Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	10/05/2011	9.90	Blood Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Abstract
Sung, Lillian	The Hospital for Sick Children	09/21/2011	9.90	Blood Lack of clarity in the definition of treatment-related mortality: pediatric acute leukemia and adult acute promyelocytic leukemia as examples. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	09/16/2011	9.90	Blood Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Abstract
Chen, Sai-Juan	Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine	08/31/2011	9.90	Blood Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Abstract
Meshinchi, Soheil	Clinical Research Division	08/26/2011	9.90	Blood Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	08/25/2011	9.90	Blood Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	08/16/2011	9.90	Blood Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Abstract
Bloomfield, Clara D	The Ohio State University Comprehensive Cancer Center	08/09/2011	9.90	Blood Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	08/09/2011	9.90	Blood TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	08/09/2011	9.90	Blood Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Abstract
Tallman, Martin S	From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt…	07/29/2011	9.90	Blood Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	07/29/2011	9.90	Blood The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Abstract
Dombret, Hervé	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	06/20/2011	9.90	Blood Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Abstract
Appelbaum, Frederick R	Clinical Research Division	06/16/2011	9.90	Blood Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Abstract
Pui, Ching-Hon	St Jude Children's Research Hospital	05/25/2011	9.90	Blood High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	05/06/2011	9.90	Blood Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Abstract
Pabst, Thomas	University Hospital and University of Berne	04/06/2011	9.90	Blood Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML. Abstract
Tefferi, Ayalew	Mayo Clinic	03/30/2011	9.90	Blood Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Abstract
Tallman, Martin S	Israel Institute of Technology	03/17/2011	9.90	Blood Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Abstract
Ganser, Arnold	Hannover Medical School	03/03/2011	9.90	Blood Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	02/23/2011	9.90	Blood CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	02/01/2011	9.90	Blood Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Abstract
Ley, Timothy J	Siteman Cancer Center	12/29/2010	9.90	Blood Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice. Abstract
Döhner, Konstanze	University Hospital of Ulm	12/21/2010	9.90	Blood Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	12/09/2010	9.90	Blood RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Abstract
Döhner, Konstanze	University Hospital of Ulm	12/02/2010	9.90	Blood The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Abstract
Weisdorf, Daniel J	Mayo Clinic Rochester	11/22/2010	9.90	Blood Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Abstract
Bloomfield, Clara D	The Ohio State University Comprehensive Cancer Center	11/02/2010	9.90	Blood The prognostic and functional role of microRNAs in acute myeloid leukemia. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	11/02/2010	9.90	Blood High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23). Abstract
Haferlach, Torsten	University Cancer Center Hamburg	10/28/2010	9.90	Blood Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Abstract
Delwel, Ruud	Erasmus University Medical Center	09/20/2010	9.90	Blood Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	08/30/2010	9.90	Blood IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Abstract
Tallman, Martin S	From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt…	08/17/2010	9.90	Blood Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	08/06/2010	9.90	Blood Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Abstract
Bloomfield, Clara D	The Ohio State University Comprehensive Cancer Center	07/23/2010	9.90	Blood FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract
Ley, Timothy J	Siteman Cancer Center	07/20/2010	9.90	Blood A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Abstract
Falini, Brunangelo	University of Perugia	07/15/2010	9.90	Blood CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	06/25/2010	9.90	Blood Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NO Abstract
Appelbaum, Frederick R	Stanford Cancer Center	06/18/2010	9.90	Blood Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Abstract
Tallman, Martin S	Israel Institute of Technology	06/17/2010	9.90	Blood How I treat acute myeloid leukemia. Abstract
Estey, Elihu H	Clinical Research Division and Southwest Oncology Group Statistical Center	06/10/2010	9.90	Blood Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Abstract
Weisdorf, Daniel J	University of Minnesota	06/10/2010	9.90	Blood Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Abstract
Bloomfield, Clara D	The Ohio State University	05/04/2010	9.90	Blood Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract
Ganser, Arnold	Hannover Medical School	04/26/2010	9.90	Blood Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Abstract
Meshinchi, Soheil	Clinical Research Division	04/22/2010	9.90	Blood Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	04/05/2010	9.90	Blood WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	03/04/2010	9.90	Blood Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	01/22/2010	9.90	Blood Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Abstract
Meshinchi, Soheil	Clinical Research Division	01/07/2010	9.90	Blood Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Abstract
Weisdorf, Daniel J	Mayo Clinic Rochester	12/23/2009	9.90	Blood Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	12/11/2009	9.90	Blood Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Abstract
Tefferi, Ayalew	Mayo Clinic	11/09/2009	9.90	Blood International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Abstract
Estey, Elihu H	Clinical Research Division and Southwest Oncology Group Statistical Center	10/30/2009	9.90	Blood Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	10/06/2009	9.90	Blood AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Abstract
Appelbaum, Frederick R	Clinical Research Division	09/28/2009	9.90	Blood Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Abstract
Tefferi, Ayalew	Mayo Clinic	08/27/2009	9.90	Blood Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Abstract
Carroll, Martin	University of Pennsylvania	08/21/2009	9.90	Blood Taking aim at protein translation in AML. Abstract
Melnick, Ari	Weill Cornell Medical College	08/03/2009	9.90	Blood MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	07/08/2009	9.90	Blood Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	06/16/2009	9.90	Blood Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	06/15/2009	9.90	Blood Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	05/14/2009	9.90	Blood Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Abstract
Falini, Brunangelo	Munich Leukemia Laboratory GmbH, Munich	05/08/2009	9.90	Blood AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	05/06/2009	9.90	Blood Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	05/04/2009	9.90	Blood Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Abstract
Stegmaier, Kimberly	Harvard Medical School	04/17/2009	9.90	Blood Identification of AML1-ETO modulators by chemical genomics. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	04/16/2009	9.90	Blood Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Abstract
Tallman, Martin S	From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt…	04/15/2009	9.90	Blood Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Abstract
Bloomfield, Clara D	The Ohio State University	04/08/2009	9.90	Blood The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Abstract
Meshinchi, Soheil	Clinical Research Division	03/20/2009	9.90	Blood Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Abstract
Dombret, Hervé	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	03/16/2009	9.90	Blood The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	03/12/2009	9.90	Blood Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Abstract
Marcucci, Guido	The Ohio State University	02/11/2009	9.90	Blood MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Abstract
Weisdorf, Daniel J	University of Minnesota	01/28/2009	9.90	Blood Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Abstract
Delwel, Ruud	Erasmus University Medical Center	01/26/2009	9.90	Blood Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Abstract
Delwel, Ruud	Erasmus University Medical Center	01/23/2009	9.90	Blood Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Abstract
Pui, Ching-Hon	St Jude Children's Research Hospital	01/08/2009	9.90	Blood Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Abstract
Relling, Mary V	St Jude Children's Research Hospital	12/09/2008	9.90	Blood Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Abstract
Björkholm, Magnus	Genetic Epidemiology Branch, DCEG, NCI, 6120 Executive Blvd, Room 7124, MSC 7236, Bethesda, MD 20892-7236	11/19/2008	9.90	Blood Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Abstract
Andreeff, Michael	University of Texas MD Anderson Cancer Center	10/28/2008	9.90	Blood CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Abstract
Appelbaum, Frederick R	Clinical Research Division	10/16/2008	9.90	Blood Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	10/02/2008	9.90	Blood Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Abstract
Delwel, Ruud	Erasmus University Medical Center	08/14/2008	9.90	Blood A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Abstract
Weissman, Irving L	Stanford University School of Medicine	02/06/2013	9.81	Proceedings of the National Academy of Sciences of the United States of America Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Abstract
Armstrong, Scott A	Harvard Medical School	03/06/2012	9.81	Proceedings of the National Academy of Sciences of the United States of America Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Abstract
Chen, Sai-Juan	Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	01/24/2011	9.81	Proceedings of the National Academy of Sciences of the United States of America C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Abstract
Marcucci, Guido	The Ohio State University	04/05/2010	9.81	Proceedings of the National Academy of Sciences of the United States of America Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Abstract
Ley, Timothy J	Washington University School of Medicine	07/27/2009	9.81	Proceedings of the National Academy of Sciences of the United States of America Acquired copy number alterations in adult acute myeloid leukemia genomes. Abstract
Weissman, Irving L	Stanford University School of Medicine	02/13/2009	9.81	Proceedings of the National Academy of Sciences of the United States of America Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Abstract
Bloomfield, C D	The Ohio State University Comprehensive Cancer Center	12/11/2013	9.56	Leukemia GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Abstract
Garcia-Manero, G	University of Texas MD Cancer Center	11/25/2013	9.56	Leukemia Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Abstract
van den Heuvel-Eibrink, M M	Erasmus MC-Sophia Children's Hospital	11/25/2013	9.56	Leukemia miR-9 is a tumor suppressor in pediatric AML with t(8;21). Abstract
Haferlach, T	MLL Munich Leukemia Laboratory, Munich	08/20/2013	9.56	Leukemia Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Abstract
Tien, H F	National Taiwan University	08/09/2013	9.56	Leukemia Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Abstract
Carroll, M	University of Pennsylvania	07/04/2013	9.56	Leukemia Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors. Abstract
Bloomfield, C D	The Ohio State University Comprehensive Cancer Center	06/14/2013	9.56	Leukemia A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Abstract
Estey, E H	University of Washington School of Medicine	06/12/2013	9.56	Leukemia Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Abstract
Tefferi, A	Mayo Clinic	04/26/2013	9.56	Leukemia Mutations and prognosis in primary myelofibrosis. Abstract
Tefferi, A	Mayo Clinic	04/22/2013	9.56	Leukemia CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Abstract
Stegmaier, K	Harvard Medical School	03/28/2013	9.56	Leukemia SYK regulates mTOR signaling in AML. Abstract
Tefferi, A	Mayo Clinic	03/27/2013	9.56	Leukemia Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Abstract
Graubert, T A	Washington University	02/27/2013	9.56	Leukemia Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Abstract
Andreeff, M	University of Texas M. D. Anderson Cancer Center	12/18/2012	9.56	Leukemia HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Abstract
Armstrong, S A	Children's Hospital	12/13/2012	9.56	Leukemia Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Abstract
Marcucci, G	The Ohio State University and The Ohio State University Comprehensive Cancer Center	11/26/2012	9.56	Leukemia Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Abstract
Armstrong, S A	Dana Farber Cancer Institute and Harvard Medical School	11/09/2012	9.56	Leukemia Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Abstract
Ravandi, F	The University of Texas MD Anderson Cancer Center	11/08/2012	9.56	Leukemia Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Abstract
Kantarjian, H M	The University of Texas	11/06/2012	9.56	Leukemia Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Abstract
Haferlach, T	MLL Munich Leukemia Laboratory, Munich	09/11/2012	9.56	Leukemia ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Abstract
Chen, S-J	Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine	02/07/2012	9.56	Leukemia Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countries. Abstract
Chen, S-J	Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine	02/02/2012	9.56	Leukemia Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases. Abstract
Andreeff, M	University of Texas M. D. Anderson Cancer Center	11/08/2011	9.56	Leukemia MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Abstract
Tefferi, A	Mayo Clinic	10/28/2011	9.56	Leukemia Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Abstract
Andreeff, M	The University of Texas MD Anderson Cancer Center	09/09/2011	9.56	Leukemia MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Abstract
Pui, C-H	St Jude Children's Research Hospital	08/26/2011	9.56	Leukemia ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Abstract
Van den Heuvel-Eibrink, M M	Erasmus MC-Sophia Children's Hospital	05/13/2011	9.56	Leukemia The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Abstract
Haferlach, T	MLL Munich Leukemia Laboratory, Munich	05/03/2011	9.56	Leukemia Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Abstract
Graubert, T A	Washington University	03/18/2011	9.56	Leukemia Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Abstract
Haferlach, T	MLL Munich Leukemia Laboratory, Munich	01/14/2011	9.56	Leukemia Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. Abstract
Garcia-Manero, G	University of Texas MD Cancer Center	11/30/2010	9.56	Leukemia Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Abstract
Tien, H-F	National Taiwan University Hospital	11/16/2010	9.56	Leukemia The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Abstract
Tefferi, A	Mayo Clinic	11/12/2010	9.56	Leukemia Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Abstract
Tefferi, A	Policlinico Universitario di Palermo	10/14/2010	9.56	Leukemia Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Abstract
van den Heuvel-Eibrink, M M	Erasmus MC-Sophia Children's Hospital	09/23/2010	9.56	Leukemia High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome. Abstract
Mullighan, C G	St Jude Children's Research Hospital	08/26/2010	9.56	Leukemia Genomic profiling of high-risk acute lymphoblastic leukemia. Abstract
Carroll, M	University of Pennsylvania	05/06/2010	9.56	Leukemia BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Abstract
Tefferi, A	Mayo Clinic	04/29/2010	9.56	Leukemia Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Abstract
Tefferi, A	Mayo Clinic	04/22/2010	9.56	Leukemia IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Abstract
Graubert, T A	Washington University	04/08/2010	9.56	Leukemia POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature. Abstract
Meshinchi, S	Clinical Research Division	04/08/2010	9.56	Leukemia Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Abstract
van den Heuvel-Eibrink, M M	Erasmus MC-Sophia Children's Hospital	04/01/2010	9.56	Leukemia EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Abstract
Döhner, H	University Hospital of Ulm	12/17/2009	9.56	Leukemia Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Abstract
Ravandi, F	The University of Texas MD Anderson Cancer Center	09/10/2009	9.56	Leukemia Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Abstract
Carroll, M	University of Pennsylvania	07/23/2009	9.56	Leukemia A robust xenotransplantation model for acute myeloid leukemia. Abstract
Chen, S-J	Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine	05/21/2009	9.56	Leukemia AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Abstract
Pui, C-H	St Jude Children's Research Hospital	03/12/2009	9.56	Leukemia Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Abstract
Levine, R L	Mayo Clinic	03/05/2009	9.56	Leukemia TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Abstract
Ravandi, F	The University of Texas MD Anderson Cancer Center	02/26/2009	9.56	Leukemia Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Abstract
Tien, H-F	National Taiwan University Hospital	02/19/2009	9.56	Leukemia Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Abstract
Andreeff, Michael	University of Texas MD Anderson Cancer Center	07/25/2009	9.56	Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Abstract
Sung, Lillian	The Hospital for Sick Children	09/05/2012	9.15	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian infections in AML research group. Abstract
Andreeff, Michael	The University of Texas MD Anderson Cancer Center	03/09/2010	7.86	Cancer research Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Abstract
Campana, Dario	National University of Singapore	04/21/2009	7.86	Cancer research Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	10/21/2010	7.80	Science translational medicine Metabolic syndromes and malignant transformation: where the twain shall meet. Abstract
Marcucci, Guido	The Ohio State University	03/14/2013	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Abstract
Ebert, Benjamin L	Harvard Medical School	01/17/2013	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Abstract
Mullighan, Charles G	University of California	05/16/2012	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	12/13/2010	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Abstract
Ebert, Benjamin L	Harvard Medical School	06/29/2010	7.74	Clinical cancer research : an official journal of the American Association for Cancer Research NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	10/23/2010	7.45	Autophagy The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Abstract
Sung, L	Pediatric Oncology Group of Ontario, Toronto	10/28/2012	6.43	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Adolescents with acute lymphoblastic leukemia treated at pediatric versus adult hospitals. Abstract
Tien, H-F	National Taiwan University	08/06/2010	6.43	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. Abstract
Tien, H-F	National Taiwan University Hospital	03/08/2009	6.43	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia. Abstract
Estey, Elihu H	Clinical Research Division and Southwest Oncology Group Statistical Center	10/18/2013	6.42	Haematologica Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Abstract
Bloomfield, Clara D	The Ohio State University	10/04/2013	6.42	Haematologica Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	06/28/2013	6.42	Haematologica Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Abstract
Falini, Brunangelo	University of Perugia	01/24/2013	6.42	Haematologica Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Abstract
Weisdorf, Daniel J	University of Minnesota	09/14/2012	6.42	Haematologica Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Abstract
Weisdorf, Daniel J	University of Minnesota	07/06/2012	6.42	Haematologica Survival for older patients with acute myeloid leukemia: a population-based study. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	07/06/2012	6.42	Haematologica Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	06/24/2012	6.42	Haematologica Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. Abstract
Ravandi, Farhad	The University of Texas M. D. Anderson Cancer Center	04/24/2012	6.42	Haematologica Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	04/17/2012	6.42	Haematologica Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. Abstract
Appelbaum, Frederick R	and University of Washington School of Medicine	02/07/2012	6.42	Haematologica Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	01/22/2012	6.42	Haematologica Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Abstract
Estey, Elihu H	Clinical Research Division and Southwest Oncology Group Statistical Center	12/01/2011	6.42	Haematologica Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Abstract
Döhner, Hartmut	UniversitÃ¤tsklinikum Ulm, Ulm	11/04/2011	6.42	Haematologica A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Abstract
Ganser, Arnold	Hannover Medical School	08/31/2011	6.42	Haematologica Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	08/22/2011	6.42	Haematologica Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	07/26/2011	6.42	Haematologica Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Abstract
Bloomfield, Clara D	The Ohio State University	06/09/2011	6.42	Haematologica Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	05/23/2011	6.42	Haematologica Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	02/28/2011	6.42	Haematologica Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Abstract
Heuser, Michael	Hannover Medical School	05/21/2010	6.42	Haematologica IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	03/10/2010	6.42	Haematologica Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	12/16/2009	6.42	Haematologica Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	10/01/2009	6.42	Haematologica Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Abstract
Falini, Brunangelo	Munich Leukemia Laboratory GmbH, Munich	12/09/2008	6.42	Haematologica Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Abstract
Döhner, Konstanze	University Hospital of Ulm	12/04/2008	6.42	Haematologica Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	02/07/2011	6.00	Current topics in developmental biology Genetic alterations targeting lymphoid development in acute lymphoblastic leukemia. Abstract
Sung, Lillian	The Hospital for Sick Children	11/13/2011	5.54	European journal of cancer (Oxford, England : 1990) Treatment-related mortality in children with acute myeloid leukaemia in Central America: incidence, timing and predictors. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	03/16/2010	5.54	European journal of cancer (Oxford, England : 1990) Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. Abstract
Falini, Brunangelo	Munich Leukemia Laboratory GmbH, Munich	12/20/2012	5.36	Blood reviews Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Abstract
Tien, H-F	National Taiwan University Hospital	11/17/2011	5.04	British journal of cancer Distinct association between aberrant methylation of Wnt inhibitors and genetic alterations in acute myeloid leukaemia. Abstract
Pabst, T	University of Bern	07/14/2010	5.04	British journal of cancer The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Abstract
Sung, L	Children's Hospital of Eastern Ontario	03/17/2009	5.04	British journal of cancer Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. Abstract
Appelbaum, Frederick R	Clinical Research Division	10/28/2013	4.94	British journal of haematology Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. Abstract
Cortes, Jorge	The University of Texas MD Anderson Cancer Center	03/27/2013	4.94	British journal of haematology Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	10/01/2012	4.94	British journal of haematology CBL mutations do not frequently occur in paediatric acute myeloid leukaemia. Abstract
Ravandi, Farhad	M.D. Anderson Cancer Center	02/24/2012	4.94	British journal of haematology Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	04/12/2010	4.94	British journal of haematology Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	03/16/2009	4.94	British journal of haematology Current status of gene expression profiling in the diagnosis and management of acute leukaemia. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	11/27/2012	4.93	Current topics in microbiology and immunology JAK-mutant myeloproliferative neoplasms. Abstract
Dombret, Hervé	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	02/04/2011	4.78	Oncotarget Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	01/10/2011	4.77	Cancer Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	11/08/2010	4.77	Cancer Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Abstract
Tallman, Martin S	From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt…	10/25/2010	4.77	Cancer Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Abstract
Cortes, Jorge	The University of Texas MD Anderson Cancer Center	10/19/2010	4.77	Cancer A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	10/19/2010	4.77	Cancer Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Abstract
Kantarjian, Hagop M	The University of Texas M. D. Anderson Cancer Center	10/19/2010	4.77	Cancer Monitoring molecular response in chronic myeloid leukemia. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	09/30/2010	4.77	Cancer Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	09/15/2010	4.77	Cancer Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Abstract
Ravandi, Farhad	The University of Texas M. D. Anderson Cancer Center	08/27/2010	4.77	Cancer Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Abstract
Dombret, Herve	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	08/10/2010	4.77	Cancer Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	07/29/2010	4.77	Cancer Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	06/24/2010	4.77	Cancer Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	05/04/2010	4.77	Cancer Characteristics of pericardial effusions in patients with leukemia. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	04/26/2010	4.77	Cancer Cause of death in patients with lower-risk myelodysplastic syndrome. Abstract
Dombret, Herve	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	03/29/2010	4.77	Cancer Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Abstract
Kantarjian, Hagop M	The University of Texas M. D. Anderson Cancer Center	02/26/2010	4.77	Cancer Adult acute lymphoblastic leukemia: concepts and strategies. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	12/16/2009	4.77	Cancer Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	08/26/2009	4.77	Cancer Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	08/26/2009	4.77	Cancer Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	08/11/2009	4.77	Cancer Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	07/10/2009	4.77	Cancer Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Abstract
Kantarjian, Hagop M	The University of Texas M. D. Anderson Cancer Center	06/29/2009	4.77	Cancer Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	05/25/2009	4.77	Cancer Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Abstract
Ravandi, Farhad	The University of Texas M. D. Anderson Cancer Center	01/05/2009	4.77	Cancer Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	11/20/2013	4.67	American journal of hematology IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	11/20/2013	4.67	American journal of hematology Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Abstract
Tefferi, Ayalew	Mayo Clinic	10/24/2013	4.67	American journal of hematology Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	09/03/2013	4.67	American journal of hematology Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. Abstract
Tefferi, Ayalew	Mayo Clinic	05/22/2013	4.67	American journal of hematology Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Abstract
Estey, Elihu H	Clinical Research Division and Southwest Oncology Group Statistical Center	03/25/2013	4.67	American journal of hematology Acute myeloid leukemia: 2013 update on risk-stratification and management. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	03/20/2013	4.67	American journal of hematology Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Abstract
Tefferi, Ayalew	Mayo Clinic	01/18/2013	4.67	American journal of hematology Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	10/31/2012	4.67	American journal of hematology FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	10/23/2012	4.67	American journal of hematology Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	06/14/2012	4.67	American journal of hematology Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Abstract
Tefferi, Ayalew	Mayo Clinic	05/22/2012	4.67	American journal of hematology Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Abstract
Tefferi, Ayalew	Mayo Clinic	05/06/2012	4.67	American journal of hematology Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications. Abstract
Tefferi, Ayalew	Mayo Clinic	03/28/2012	4.67	American journal of hematology Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Abstract
Tefferi, Ayalew	Mayo Clinic	02/14/2012	4.67	American journal of hematology Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	01/07/2012	4.67	American journal of hematology Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Abstract
Estey, Elihu H	Clinical Research Division and Southwest Oncology Group Statistical Center	12/19/2011	4.67	American journal of hematology Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Abstract
Tefferi, Ayalew	Mayo Clinic	11/17/2011	4.67	American journal of hematology Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	05/19/2011	4.67	American journal of hematology Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. Abstract
Tefferi, Ayalew	Mayo Clinic	04/27/2011	4.67	American journal of hematology Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	04/20/2011	4.67	American journal of hematology Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Abstract
Tefferi, Ayalew	Mayo Clinic	03/28/2011	4.67	American journal of hematology Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. Abstract
Tefferi, Ayalew	Mayo Clinic	02/25/2011	4.67	American journal of hematology Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	12/24/2010	4.67	American journal of hematology Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Abstract
Tefferi, Ayalew	Mayo Clinic and Mayo Clinic College of Medicine	03/31/2010	4.67	American journal of hematology Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Abstract
Campana, Dario	National University of Singapore	02/05/2013	4.52	Current opinion in hematology Should evaluation for minimal residual disease be routine in acute myeloid leukemia? Abstract
Campana, Dario	National University of Singapore	06/06/2012	4.52	Current opinion in hematology Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Abstract
Weisdorf, Daniel J	Mayo Clinic Rochester	10/12/2011	4.52	Current opinion in hematology Allogeneic stem cell transplantation in first complete remission. Abstract
Marcucci, Guido	The Ohio State University	05/26/2009	4.52	Current opinion in hematology Molecular signatures in acute myeloid leukemia. Abstract
Döhner, Konstanze	University Hospital of Ulm	05/26/2009	4.52	Current opinion in hematology Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	12/05/2008	4.52	Current opinion in hematology Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Abstract
Tallman, Martin S	From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt…	12/16/2013	4.41	Journal of the National Comprehensive Cancer Network : JNCCN Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia. Abstract
Tallman, Martin S	From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt…	09/13/2013	4.41	Journal of the National Comprehensive Cancer Network : JNCCN Acute myeloid leukemia, version 2.2013. Abstract
Appelbaum, Frederick R	and University of Washington School of Medicine	03/11/2011	4.41	Journal of the National Comprehensive Cancer Network : JNCCN Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation. Abstract
Tallman, M S	Memorial Sloan-Kettering Cancer Center	06/19/2012	4.33	Current cancer drug targets Novel and emerging drugs for acute myeloid leukemia. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	07/09/2010	4.23	Drugs Current and future management options for myelodysplastic syndromes. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	10/07/2010	4.10	Current opinion in oncology Molecular genetics in acute myeloid leukemia. Abstract
Löwenberg, Bob	University Hospital La Fe	10/12/2009	4.10	Current opinion in oncology FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Abstract
Sung, Lillian	The Hospital for Sick Children	09/06/2013	4.09	PloS one Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	08/15/2013	4.09	PloS one Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. Abstract
Sung, Lillian	The Hospital for Sick Children	04/26/2013	4.09	PloS one Infectious events prior to chemotherapy initiation in children with acute myeloid leukemia. Abstract
Ley, Timothy J	Siteman Cancer Center	10/08/2012	4.09	PloS one Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice. Abstract
Sung, Lillian	The Hospital for Sick Children	08/22/2012	4.09	PloS one Low socioeconomic status is associated with prolonged times to assessment and treatment, sepsis and infectious death in pediatric fever in El Salvador. Abstract
Graubert, Timothy A	Washington University School of Medicine	11/17/2010	4.07	BMC genomics Integrated genomics of susceptibility to alkylator-induced leukemia in mice. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	11/25/2013	4.02	Bone Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocol. Abstract
van den Heuvel-Eibrink, M M	Erasmus MC-Sophia Children's Hospital	10/16/2010	4.02	Bone Germline variation in the MTHFR and MTRR genes determines the nadir of bone density in pediatric acute lymphoblastic leukemia: a prospective study. Abstract
Meshinchi, Soheil	Clinical Research Division	11/19/2013	3.99	Seminars in hematology Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	10/03/2013	3.99	Seminars in hematology Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Abstract
Chen, Sai-Juan	Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine	03/19/2013	3.99	Seminars in hematology DNA methyltransferases in hematologic malignancies. Abstract
Armstrong, Scott A	Harvard Medical School	12/22/2008	3.99	Seminars in hematology Leukemia stem cells and human acute lymphoblastic leukemia. Abstract
Weisdorf, Daniel J	University of Minnesota	09/06/2013	3.87	Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Providing personalized prognostic information for adult leukemia survivors. Abstract
Weisdorf, Daniel J	University of Minnesota	03/16/2012	3.87	Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Abstract
Weisdorf, Daniel J	Mayo Clinic Rochester	07/31/2011	3.87	Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Abstract
Weisdorf, Daniel J	Mayo Clinic Rochester	11/01/2010	3.87	Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Abstract
Dombret, H	University Paris 7	03/19/2012	3.75	Bone marrow transplantation Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Abstract
Weisdorf, D J	University of Minnesota	05/23/2011	3.75	Bone marrow transplantation Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Abstract
Ganser, A	Hannover Medical School	06/14/2010	3.75	Bone marrow transplantation Prognostic factors in allo-SCT of elderly patients with AML. Abstract
Haferlach, T	MLL Munich Leukemia Laboratory, Munich	04/13/2009	3.75	Bone marrow transplantation Interactive diagnostics in the indication to allogeneic SCT in AML. Abstract
Ravandi, F	The University of Texas MD Anderson Cancer Center	01/19/2009	3.75	Bone marrow transplantation Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Abstract
Pui, C-H	St Jude Children's Research Hospital	07/30/2009	3.68	AJNR. American journal of neuroradiology Voxel-based analysis of T2 hyperintensities in white matter during treatment of childhood leukemia. Abstract
Sung, Lillian	The Hospital for Sick Children	01/13/2014	3.58	The Pediatric infectious disease journal Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group. Abstract
Sung, Lillian	The Hospital for Sick Children	07/10/2013	3.58	The Pediatric infectious disease journal Clostridium difficile infection in pediatric acute myeloid leukemia: from the Canadian Infections in Acute Myeloid Leukemia Research Group. Abstract
Sung, Lillian	The Hospital for Sick Children	11/25/2009	3.58	The Pediatric infectious disease journal Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	01/31/2012	3.50	Seminars in oncology Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	09/29/2011	3.50	Seminars in oncology Molecular biology of myelodysplastic syndromes. Abstract
Ebert, Benjamin L	Harvard Medical School	09/29/2011	3.50	Seminars in oncology Molecular dissection of the 5q deletion in myelodysplastic syndrome. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	09/29/2011	3.50	Seminars in oncology Integrating care for patients with lower risk myelodysplastic syndrome. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	09/29/2011	3.50	Seminars in oncology Treatment of higher-risk myelodysplastic syndrome. Abstract
Heuser, Michael	Hannover Medical School	03/27/2012	3.31	Genes, chromosomes & cancer Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	12/08/2011	3.31	Genes, chromosomes & cancer ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	11/10/2011	3.31	Genes, chromosomes & cancer Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Abstract
Döhner, Konstanze	University Hospital of Ulm	11/11/2010	3.31	Genes, chromosomes & cancer Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	02/15/2010	3.31	Genes, chromosomes & cancer Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Abstract
Ravandi, Farhad	M.D. Anderson Cancer Center	03/22/2011	3.21	Expert opinion on emerging drugs Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	09/20/2012	3.21	Expert opinion on pharmacotherapy Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Abstract
Ravandi, Farhad	The University of Texas M. D. Anderson Cancer Center	04/20/2012	3.16	Future oncology (London, England) Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial. Abstract
Dombret, Hervé	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	10/26/2009	3.16	Future oncology (London, England) Clofarabine for the treatment of adult acute myeloid leukemia. Abstract
Sung, Lillian	The Hospital for Sick Children	06/04/2013	3.01	BMC cancer Infections in pediatric acute promyelocytic leukemia: from the canadian infections in acute myeloid leukemia research group. Abstract
Tien, Hwei-Fang	National Taiwan University Hospital	03/08/2013	3.01	BMC cancer Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	11/13/2013	2.92	Leukemia research Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	12/10/2012	2.92	Leukemia research Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. Abstract
Tallman, Martin S	Memorial Sloan-Kettering Cancer Center	10/24/2012	2.92	Leukemia research Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	09/15/2012	2.92	Leukemia research Molecular genetics in myelodysplastic syndromes. Abstract
Pabst, Thomas	University Hospital and University of Berne	06/23/2012	2.92	Leukemia research The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential. Abstract
Dombret, Hervé	Department of Hematology, HÃ´pital Edouard Herriot, Lyon	05/28/2012	2.92	Leukemia research Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	05/01/2012	2.92	Leukemia research Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Abstract
Bhatia, Ravi	Division of Hematopoietic Stem Cell and Leukemia Research and.	04/12/2012	2.92	Leukemia research Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors. Abstract
Tallman, Martin S	Memorial Sloan-Kettering Cancer Center	12/15/2011	2.92	Leukemia research Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Abstract
van den Heuvel-Eibrink, Marry M	Erasmus MC-Sophia Children's Hospital	10/12/2010	2.92	Leukemia research KIAA1524: A novel MLL translocation partner in acute myeloid leukemia. Abstract
Maciejewski, Jaroslaw P	Cleveland Clinic	03/23/2010	2.92	Leukemia research Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Abstract
Pabst, Thomas	University Hospital and University of Berne	12/16/2009	2.92	Leukemia research Complexity of miR-223 regulation by CEBPA in human AML. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	08/13/2009	2.92	Leukemia research Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	05/02/2009	2.92	Leukemia research Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH). Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	10/01/2010	2.91	Experimental hematology A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	05/05/2009	2.91	Experimental hematology Proteomics-based prediction of clinical response in acute myeloid leukemia. Abstract
Andreeff, Michael	The University of Texas MD Anderson Cancer Center	04/19/2011	2.87	Journal of cellular biochemistry Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. Abstract
Kantarjian, Hagop M	The University of Texas M. D. Anderson Cancer Center	10/05/2012	2.85	European journal of clinical pharmacology Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	01/14/2011	2.83	Current opinion in pediatrics How new advances in genetic analysis are influencing the understanding and treatment of childhood acute leukemia. Abstract
Falini, Brunangelo	University of Perugia	03/18/2013	2.80	Protein science : a publication of the Protein Society Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. Abstract
Kantarjian, Hagop M	The University of Texas M. D. Anderson Cancer Center	11/18/2013	2.65	Expert review of anticancer therapy Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Abstract
Ravandi, Farhad	M.D. Anderson Cancer Center	10/16/2013	2.64	Best practice & research. Clinical haematology Relapsed acute myeloid leukemia: why is there no standard of care? Abstract
Appelbaum, Frederick R	Clinical Research Division	10/16/2013	2.64	Best practice & research. Clinical haematology Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	10/15/2013	2.64	Best practice & research. Clinical haematology Molecular pathogenesis of AML: translating insights to the clinic. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	10/25/2012	2.64	Best practice & research. Clinical haematology Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Abstract
Mullighan, Charles G	Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105	11/06/2011	2.64	Best practice & research. Clinical haematology Genomic profiling of B-progenitor acute lymphoblastic leukemia. Abstract
Appelbaum, Frederick R	Clinical Research Division	11/02/2011	2.64	Best practice & research. Clinical haematology The role of hematopoietic cell transplantation as therapy for myelodysplasia. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	08/12/2010	2.64	Best practice & research. Clinical haematology The role of multiparameter flow cytometry for disease monitoring in AML. Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	12/04/2009	2.64	Best practice & research. Clinical haematology Mechanisms of mutations in myeloproliferative neoplasms. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	08/24/2009	2.64	Best practice & research. Clinical haematology Gene expression profiling in acute myeloid leukaemia (AML). Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	10/22/2013	2.64	Cancer HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Abstract
Pui, Ching-Hon	St Jude Children's Research Hospital	03/01/2013	2.64	Cancer Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Abstract
Sung, Lillian	The Hospital for Sick Children	11/16/2012	2.64	Cancer Outcome of children treated for relapsed acute lymphoblastic leukemia in Central America. Abstract
Ravandi, Farhad	The University of Texas M. D. Anderson Cancer Center	06/15/2012	2.64	Cancer Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Abstract
Ravandi, Farhad	M.D. Anderson Cancer Center	05/08/2012	2.64	Cancer Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	02/27/2012	2.64	Cancer Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	01/31/2012	2.64	Cancer Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Abstract
Kantarjian, Hagop M	The University of Texas MD Anderson Cancer Center	01/26/2012	2.64	Cancer Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	01/17/2012	2.64	Cancer Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	10/21/2011	2.64	Cancer Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Abstract
Estey, Elihu H	Stanford University School of Medicine	09/16/2011	2.64	Cancer Impact of residual normal metaphases in core binding factor acute myeloid leukemia. Abstract
Appelbaum, Frederick R	Clinical Research Division	09/16/2011	2.64	Cancer Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	04/26/2011	2.64	Cancer Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Abstract
Sung, Lillian	The Hospital for Sick Children	03/28/2011	2.64	Cancer Treatment-related mortality in children with acute lymphoblastic leukemia in Central America. Abstract
Cortes, Jorge	The University of Texas MD Anderson Cancer Center	02/11/2011	2.64	Cancer FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Abstract
Heuser, Michael	Hannover Medical School	12/12/2012	2.62	Annals of hematology Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Abstract
Heuser, Michael	Hannover Medical School	04/10/2012	2.62	Annals of hematology Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	03/02/2010	2.62	Annals of hematology Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Abstract
Ganser, Arnold	Hannover Medical School	11/17/2011	2.61	European journal of haematology Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Abstract
Tefferi, Ayalew	Mayo Clinic	11/30/2009	2.61	European journal of haematology Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. Abstract
Tefferi, Ayalew	Mayo Clinic	01/09/2009	2.61	European journal of haematology Conventional cytogenetics in myelofibrosis: literature review and discussion. Abstract
Sung, Lillian	The Hospital for Sick Children	01/15/2011	2.60	Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Pneumatosis intestinalis in children with acute lymphoblastic leukemia and acute myeloid leukemia. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	02/14/2014	2.58	Leukemia & lymphoma Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. Abstract
Sung, Lillian	The Hospital for Sick Children	11/19/2013	2.58	Leukemia & lymphoma Early deaths in pediatric acute leukemia: a population-based study. Abstract
Marcucci, Guido	The Ohio State University	11/01/2013	2.58	Leukemia & lymphoma Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. Abstract
Ravandi, Farhad	M.D. Anderson Cancer Center	10/09/2013	2.58	Leukemia & lymphoma Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Abstract
Ravandi, Farhad	M.D. Anderson Cancer Center	08/28/2013	2.58	Leukemia & lymphoma Acute myeloid leukemia in the elderly: do we know who should be treated and how? Abstract
Pabst, Thomas	UniversitÃ¤tsspital Basel , Basel	05/02/2013	2.58	Leukemia & lymphoma Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). Abstract
Heuser, Michael	Hannover Medical School	11/15/2011	2.58	Leukemia & lymphoma Update on cytogenetic and molecular changes in myelodysplastic syndromes. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	01/11/2011	2.58	Leukemia & lymphoma Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Abstract
Ravandi, Farhad	M.D. Anderson Cancer Center	04/28/2010	2.58	Leukemia & lymphoma Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Abstract
Sung, Lillian	The Hospital for Sick Children	04/28/2010	2.58	Leukemia & lymphoma Gastrointestinal complications in children with acute myeloid leukemia. Abstract
Kantarjian, Hagop	The University of Texas M. D. Anderson Cancer Center	08/13/2013	2.56	Journal of cancer research and clinical oncology The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. Abstract
Estey, Elihu H	Stanford University School of Medicine	09/03/2012	2.55	Current oncology reports Acute myeloid leukemia with normal cytogenetics. Abstract
Carroll, Martin	University of Pennsylvania	11/03/2010	2.55	Current oncology reports Targeted signal transduction therapies in myeloid malignancies. Abstract
Campana, Dario	National University of Singapore	06/26/2013	2.53	Cytometry. Part B, Clinical cytometry Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Abstract
Haferlach, Torsten	University Cancer Center Hamburg	01/02/2013	2.53	Cytometry. Part B, Clinical cytometry Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	12/05/2011	2.53	Cytometry. Part B, Clinical cytometry Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia. Abstract
Haferlach, Torsten	MLL Munich Leukemia Laboratory, Munich	10/06/2009	2.53	Cytometry. Part B, Clinical cytometry Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. Abstract
Garcia-Manero, Guillermo	The University of Texas MD Anderson Cancer Center	11/29/2011	2.38	Epigenomics Histone methylation in myelodysplastic syndromes. Abstract
Sung, L	Children's Hospital of Eastern Ontario	02/26/2013	2.25	Mycoses Invasive fungal infections in paediatric acute myeloid leukaemia. Abstract
Tallman, Martin S	Roosevelt Hospital Center	05/22/2012	2.14	Medical oncology (Northwood, London, England) Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). Abstract
Levine, Ross L	Memorial Sloan-Kettering Cancer Center	08/21/2012	2.07	Hematology/oncology clinics of North America Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Abstract
Cortes, Jorge	The University of Texas M. D. Anderson Cancer Center	10/19/2011	2.07	Hematology/oncology clinics of North America Chronic myeloid leukemia: mechanisms of resistance and treatment. Abstract
Ebert, Benjamin L	Harvard Medical School	04/02/2010	2.07	Hematolog